Camelid VHH Antibodies and scFvs: Structural Features, Applications, and Limitations

Overview of Antibody Fragments

Antibody fragments have become indispensable in modern biotechnology due to their smaller size, improved tissue penetration, and suitability for engineered constructs. Among these, camelid VHH nanobodies (single-domain antibodies) and single-chain variable fragments (scFvs) represent two widely studied and applied formats. Both can be produced recombinantly and tailored for diagnostic or therapeutic use, yet their origins, molecular structures, and functional properties are distinct.

Understanding the differences between these formats is essential for researchers when selecting the right scaffold for applications such as imaging, targeted therapies, and intracellular studies.

Origins and Molecular Composition

The structural foundation of each fragment stems from how they are derived and assembled.

Camelid Nanobody (VHH)

VHHs are the antigen-binding domains of heavy-chain-only antibodies (HCAbs) naturally found in Camelidae species such as camels, llamas, and alpacas. They function independently without requiring light chains, with an approximate molecular weight of 15 kDa.

Key properties of VHHs include:

• Naturally occurring single-domain configuration

• Long and diverse CDR3 loops enabling recognition of recessed epitopes

• Compact β-barrel framework stabilized by disulfide bonds

• High solubility and conformational stability

Single-Chain Variable Fragment (scFv)

scFvs are engineered fragments derived from conventional antibodies. They are created by genetically linking the VH and VL domains with a flexible peptide linker, yielding a construct of 25–30 kDa.

Key properties of scFvs include:

• Recombinant format mimicking Fab fragments

• Dependence on VH–VL pairing for antigen recognition

• Variable solubility and stability depending on linker design

• High adaptability for engineered platforms such as CAR-T

Structural and Functional Differences

The differences in design directly affect folding, binding, and functional performance.

• Epitope recognition

• VHHs: Access to concave and hidden epitopes due to elongated CDR3 loops.

• scFvs: Prefer surface-level epitopes accessible to VH–VL pairing.

• Stability and folding

• VHHs: Naturally stable, capable of refolding after denaturation, and resistant to aggregation.

• scFvs: More prone to misfolding and aggregation, especially in bacterial expression.

• Size and solubility

• VHHs: Small, soluble, and efficient in tissue penetration.

• scFvs: Larger, less soluble, and often require optimization for expression.

Therapeutic Applications

VHHs and scFvs have found unique niches in therapeutic and diagnostic development.

• VHH Antibodies

• FDA-approved drug: Caplacizumab (anti-vWF)

• Oncology: Tumor penetration due to small size

• Infectious disease: Viral neutralization and enzyme inhibition

• Diagnostics: PET imaging, live-cell tracking, biosensors

• scFvs

• Core component of CAR-T therapies, e.g., CD19-directed scFvs

• Used in antibody-drug conjugates (ADCs)

• Diagnostic tools such as ELISA and flow cytometry

Engineering and Humanization

Both VHHs and scFvs undergo engineering to improve safety and performance.

• VHHs: Require humanization to reduce immunogenicity while preserving framework residues critical for folding. Engineering extends to multivalency, fluorescent fusion proteins, and plant-based expression systems for scalable output.

• scFvs: Humanization is more straightforward since they derive from conventional antibodies. However, VH–VL mispairing may compromise stability, requiring careful linker design and optimization.

Clinical and Preclinical Use

Both antibody fragments have clinical relevance, though in different contexts.

• VHHs: Expanding roles in oncology, infectious diseases, and CNS-targeting therapies. Their solubility and small size also make them ideal for lateral flow assays and imaging platforms.

• scFvs: Well established in CAR-T constructs and widely used in preclinical models for diagnostics, bispecific antibodies, and affinity purification tools.

Limitations and Considerations

• VHH Nanobodies

• Short serum half-life requiring half-life extension strategies (Fc fusion, HSA binding, PEGylation).

• Lack of Fc effector functions (ADCC, CDC).

• Potential immunogenicity without humanization.

• scFvs

• Susceptible to aggregation and stability issues in microbial systems.

• Larger size reduces tissue penetration compared to VHHs.

• More costly production in mammalian hosts.

Careful selection depends on application context, production strategy, and therapeutic goals.

Conclusion

VHH antibodies and scFvs are complementary tools in antibody engineering. VHHs provide stability, scalability, and unique epitope access, making them attractive for imaging and cost-sensitive applications. scFvs remain versatile in engineered therapies such as CAR-T and ADCs but face challenges in stability and scalability. Both scaffolds continue to evolve with engineering improvements, ensuring their place in therapeutic pipelines and diagnostic platforms.

References:

1. Koch-Nolte, F. (2024). Nanobody-based heavy chain antibodies and chimeric antibodies. Immunological Reviews, 328(1), 466–472. https://doi.org/10.1111/imr.13385

2. Cong, Y., Devoogdt, N., Lambin, P., Dubois, L. J., & Yaromina, A. (2024). Promising diagnostic and therapeutic approaches based on VHHs for cancer management. Cancers, 16(2), 371. https://doi.org/10.3390/cancers16020371

3. Zhang, C., et al. “Engineering CAR-T cells” in Biomarker Research (2017).
   A foundational review describing how scFv is used in CAR design (linking VH and VL domains via a peptide linker) and the challenges of expression, stability, and functional integration. BioMed Central